3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cisplatin
9
pembrolizumab
7
Radiosurgery
6
Gemcitabine
6
Paclitaxel
5
Dexamethasone
5
Taxes
4
Carboplatin
4
trametinib
3
ibrutinib
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Fluorouracil
3
Erlotinib Hydrochloride
3
Blood Specimen Collection
3
Ascorbic Acid
3
venetoclax
2
veliparib
2
tocilizumab
2
pazopanib
2
obinutuzumab
2
naquotinib
2
lenvatinib
2
fludarabine
2
enzalutamide
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn